Autodesk On Track for Highest Close Since January 2022 — Data Talk
Autodesk, Inc. (ADSK) is currently at $269.68, up $11.45 or 4.43%
--Would be highest close since Jan. 11, 2022, when it closed at $270.63
--On pace for largest percent increase since June 17, 2024, when it rose 6.48%
--Currently up five of the past six days
--Currently up two consecutive days; up 5.91% over this period
--Best two day stretch since the two days ending June 18, 2024, when it rose 8.08%
--Up 8.95% month-to-date; on pace for best month since June 2024, when it rose 22.74%
--Up 10.76% year-to-date
--Down 21.21% from its all-time closing high of $342.27 on Aug. 25, 2021
--Up 22.57% from 52 weeks ago (Sept. 1, 2023), when it closed at $220.02
--Would be a new 52-week closing high
--Up 38.19% from its 52-week closing low of $195.15 on Oct. 27, 2023
--Traded as high as $275.68; highest intraday level since March 1, 2024, when it hit $279.53
--Up 6.76% at today's intraday high; largest intraday percent increase since June 17, 2024, when it rose as much as 7.5%
--Second best performer in the S&P 500 today
--Fourth best performer in the Nasdaq 100 today
All data as of 9:38:52 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
August 30, 2024 09:55 ET (13:55 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks